TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05211323
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05594992
Drug: JR-141
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN TRANSFERRIN RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JR-141 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN IDURONATE-2-SULFATASE, DISULFIDE WITH HUMAN-MUS MUSCULUS MONO
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: IV infusion, 2.0 mg/kg/week
Study: NCT06201234
Drug: Olaparib + Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
Study: NCT06201234
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 600 mg orally daily
Study: NCT05936268
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg/table
Study: NCT05293964
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
Study: NCT05293964
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
Study: NCT05046184
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
Study: NCT05046184
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
Study: NCT05838573
Drug: Metformin treatment
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
Study: NCT06029127
Drug: BGB-A445
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously at protocol defined dose
Study: NCT05660681
Drug: glycerin 0.7%/PEG 400 0.3%
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop with active agents from the OTC Monograph.
Study: NCT06029127
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously
Study: NCT06029127
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg administered intravenously
Study: NCT06029127
Drug: BGB-15025
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at protocol defined dose
Study: NCT05900141
Drug: Pelacarsen
Normalized name: Pelacarsen
DrugBank: Pelacarsen (DB16284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen 80mg s.c. monthly
Study: NCT06401356
Drug: Pelabresib
Normalized name: Pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Study: NCT05437263
Drug: Brepocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Brepocitinib
Study: NCT06490731
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexmedetomidine
Study: NCT05297903
Drug: XmAb20717
Normalized name: Anti-pd1/ctla4 bispecific antibody xmab20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg IV
Study: NCT06490731
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients Will receive ketamine
Study: NCT05921604
Drug: Baclofen 10mg
Normalized name: BACLOFEN 10MG TAB
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
Study: NCT05921604
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
Study: NCT05828511
Drug: Linvoseltamab
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linvoseltamab will be administered by intravenous (IV) infusion
Study: NCT05273996
Drug: Sertraline, bupropion, desvenlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
Study: NCT06517823
Drug: Etoricoxib + Cyanocobalamin fixed dose
Normalized name: etoricoxib
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 90 mg / 0.50 mg a day
Study: NCT06352424
Drug: BI 456906
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 456906
Study: NCT06352424
Drug: BI 1820237
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1820237
Study: NCT05136690
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine 21 mg transdermal nicotine patch.
Study: NCT05010421
Drug: Clobetasol 0.05% Emollient Top Cream
Normalized name: CLOBETASOL 0.05% EMOLLIENT TOP CREAM
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid treatment of affected vulvar skin areas.
Study: NCT05830084
Drug: regorafenib tablet
Normalized name: Regorafenib Tablets
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)
Study: NCT06680245
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
Study: NCT06378437
Drug: GLB-001
DrugBank: LB-001 (DB17685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally according to the assigned treatment schedule
Study: NCT06709066
Drug: mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
Study: NCT06709066
Drug: succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
Study: NCT06709417
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg iv Q3W
Study: NCT06710470
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product label
Study: NCT06710470
Drug: Systemic psoriasis medications
Normalized name: salicylic acid Medicated Shampoo [Nizoral Psoriasis]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product label
Study: NCT06708845
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy
Study: NCT05653024
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 puffs of 100 mcg inhaled salbutamol administered with spacer
Study: NCT06710184
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin bolus of 300 mg followed by 75 mg daily until CAG
Study: NCT06710184
Drug: Fondaparinux Sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)
Study: NCT06706921
Drug: 18F-Fluciclovine PET/CT Scan
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
Study: NCT04776694
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05232110
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06383572
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05467176
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
Study: NCT06383572
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06383572
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth
Study: NCT05578872
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab administered by intravenous (IV) infusion
Study: NCT05578872
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered by intravenous (IV) infusion
Study: NCT06052748
Drug: AD-223A
Normalized name: Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
DrugBank: Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (DB10999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT04731038
Drug: Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a single-arm study with all patients receiving these four drugs.
Study: NCT05361109
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
Study: NCT05742698
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
Study: NCT04855929
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered by intravenous (IV) infusion
Study: NCT06036836
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration of capsule
Study: NCT04786067
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
Study: NCT05086250
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
Study: NCT05086250
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Study: NCT06331624
Drug: Tazarotene (GRI-0621)
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 4.5mg soft gel capsule
Study: NCT06319638
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
Study: NCT05872854
Drug: Hypericin
Normalized name: Hypericin
DrugBank: Hypericin (DB13014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
Study: NCT06364410
Drug: Azenosertib
Normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04648969
Drug: kisspeptin 112-121
Normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
Study: NCT04648969
Drug: GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 intravenous dose of GnRH
Study: NCT05148299
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20-cc glass vials-1080 mg
Study: NCT06558084
Drug: CDK4/6 Inhibitor
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor in first and second lines
Study: NCT06402630
Drug: STS01
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study: NCT06111521
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06111521
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06111521
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT04416633
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500-mg/120-mg IV
Study: NCT04763928
Drug: Venetoclax+Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes.
Study: NCT05385185
Drug: Camrelizumab or envafolimab
Normalized name: Medicated Pad or Tape
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
Study: NCT06251180
Drug: Rocbrutinib
Normalized name: Rocbrutinib
DrugBank: Rocbrutinib (DB19445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Study: NCT06251180
Drug: Vincristin
Normalized name: Vincristin
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study: NCT06251180
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Study: NCT04749667
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic saline
Study: NCT06446960
Drug: Lidocaine 20mg/ml
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
Study: NCT06446960
Drug: Levobupivacaine Hydrochloride 1.25 MG/ML
Normalized name: levobupivacaine hydrochloride 1.25 MG/ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
Study: NCT06446960
Drug: Sodium Chloride 0.9% Inj
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
Study: NCT06492616
Drug: Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral tablets
Study: NCT06492616
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as oral tablets
Study: NCT06492616
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as oral tablets
Study: NCT06492616
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as oral tablets
Study: NCT06492616
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as oral tablets
Study: NCT06031844
Drug: DFV890
Normalized name: DFV890
DrugBank: DFV890 (DB16461)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral film-coated tablets
Study: NCT04538573
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented.
Study: NCT04862221
Drug: Equine anti-thymocyte globulin
Normalized name: Anti-thymocyte Globulin (Equine)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
Study: NCT04862221
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
Study: NCT04862221
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.